vorinostat has been researched along with Dysmyelopoietic Syndromes in 16 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the safety and efficacy of the combination of the histone deacetylase inhibitor vorinostat with idarubicin and ara-C (cytarabine) in patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS)." | 9.16 | Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. ( Bekele, NB; Borthakur, G; Brandt, M; Cortes, JE; de Lima, M; Faderl, S; Garcia-Manero, G; Hu, Y; Jabbour, E; Kadia, TM; Kantarjian, HM; Konopleva, MY; McCue, D; Newsome, WM; Pierce, SR; Ravandi, F; Tambaro, FP; Yang, H, 2012) |
| "Vorinostat (suberoylanilide hydroxamic acid, SAHA) is a histone deacetylase inhibitor active clinically in cutaneous T-cell lymphoma and preclinically in leukemia." | 9.13 | Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. ( Bueso-Ramos, C; Chen, C; Cortes, J; Faderl, S; Fantin, VR; Ferrajoli, A; Frankel, SR; Garcia-Manero, G; Hardwick, JS; Kantarjian, HM; Koller, C; Loboda, A; Morris, G; Randolph, SS; Reilly, JF; Richon, VM; Ricker, JL; Rosner, G; Secrist, JP; Wierda, WG; Yang, H, 2008) |
| "Vorinostat is an epigenetic targeted drug belonging to the histone deacetylase (HDAC) inhibitors family." | 6.47 | Vorinostat in acute myeloid leukemia and myelodysplastic syndromes. ( Prebet, T; Vey, N, 2011) |
| "To evaluate the safety and efficacy of the combination of the histone deacetylase inhibitor vorinostat with idarubicin and ara-C (cytarabine) in patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS)." | 5.16 | Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. ( Bekele, NB; Borthakur, G; Brandt, M; Cortes, JE; de Lima, M; Faderl, S; Garcia-Manero, G; Hu, Y; Jabbour, E; Kadia, TM; Kantarjian, HM; Konopleva, MY; McCue, D; Newsome, WM; Pierce, SR; Ravandi, F; Tambaro, FP; Yang, H, 2012) |
| "Vorinostat (suberoylanilide hydroxamic acid, SAHA) is a histone deacetylase inhibitor active clinically in cutaneous T-cell lymphoma and preclinically in leukemia." | 5.13 | Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. ( Bueso-Ramos, C; Chen, C; Cortes, J; Faderl, S; Fantin, VR; Ferrajoli, A; Frankel, SR; Garcia-Manero, G; Hardwick, JS; Kantarjian, HM; Koller, C; Loboda, A; Morris, G; Randolph, SS; Reilly, JF; Richon, VM; Ricker, JL; Rosner, G; Secrist, JP; Wierda, WG; Yang, H, 2008) |
| "Vorinostat is an epigenetic targeted drug belonging to the histone deacetylase (HDAC) inhibitors family." | 2.47 | Vorinostat in acute myeloid leukemia and myelodysplastic syndromes. ( Prebet, T; Vey, N, 2011) |
| "Vorinostat is a HDACi which has produced responses in these disorders." | 1.39 | Vorinostat induces apoptosis and differentiation in myeloid malignancies: genetic and molecular mechanisms. ( Almeida, AM; Belo, H; Cardoso, BA; Silva, G, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 14 (87.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sekeres, MA | 2 |
| Othus, M | 1 |
| List, AF | 1 |
| Odenike, O | 1 |
| Stone, RM | 1 |
| Gore, SD | 1 |
| Litzow, MR | 1 |
| Buckstein, R | 1 |
| Fang, M | 1 |
| Roulston, D | 1 |
| Bloomfield, CD | 1 |
| Moseley, A | 1 |
| Nazha, A | 1 |
| Zhang, Y | 1 |
| Velasco, MR | 1 |
| Gaur, R | 1 |
| Atallah, E | 1 |
| Attar, EC | 1 |
| Cook, EK | 1 |
| Cull, AH | 1 |
| Rauh, MJ | 1 |
| Appelbaum, FR | 1 |
| Erba, HP | 1 |
| Craddock, C | 1 |
| Glasser, CL | 1 |
| Lee, A | 1 |
| Eslin, D | 1 |
| Marks, L | 1 |
| Modak, S | 1 |
| Glade Bender, JL | 1 |
| Kubasch, AS | 1 |
| Platzbecker, U | 1 |
| Warlick, ED | 1 |
| Cao, Q | 1 |
| Miller, J | 1 |
| Prebet, T | 3 |
| Braun, T | 2 |
| Beyne-Rauzy, O | 1 |
| Dreyfus, F | 1 |
| Stammatoullas, A | 1 |
| Wattel, E | 2 |
| Ame, S | 1 |
| Raffoux, E | 1 |
| Delaunay, J | 2 |
| Charbonnier, A | 1 |
| Adès, L | 1 |
| Fenaux, P | 2 |
| Vey, N | 3 |
| Kirschbaum, M | 1 |
| Gojo, I | 1 |
| Goldberg, SL | 1 |
| Bredeson, C | 1 |
| Kujawski, LA | 1 |
| Yang, A | 1 |
| Marks, P | 1 |
| Frankel, P | 1 |
| Sun, X | 1 |
| Tosolini, A | 1 |
| Eid, JE | 1 |
| Lubiniecki, GM | 1 |
| Issa, JP | 1 |
| Ornstein, MC | 1 |
| Mukherjee, S | 1 |
| Cony-Makhoul, P | 1 |
| Dimicoli, S | 1 |
| Wickenhauser, S | 1 |
| Lejeune, J | 1 |
| Chevret, S | 1 |
| Chermat, F | 1 |
| Scott, BL | 1 |
| Aldabagh, B | 1 |
| Patel, RR | 1 |
| Honda, K | 1 |
| Maki, K | 1 |
| Mitani, K | 1 |
| Garcia-Manero, G | 2 |
| Tambaro, FP | 1 |
| Bekele, NB | 1 |
| Yang, H | 2 |
| Ravandi, F | 1 |
| Jabbour, E | 1 |
| Borthakur, G | 1 |
| Kadia, TM | 1 |
| Konopleva, MY | 1 |
| Faderl, S | 2 |
| Cortes, JE | 1 |
| Brandt, M | 1 |
| Hu, Y | 1 |
| McCue, D | 1 |
| Newsome, WM | 1 |
| Pierce, SR | 1 |
| de Lima, M | 1 |
| Kantarjian, HM | 2 |
| Silva, G | 1 |
| Cardoso, BA | 1 |
| Belo, H | 1 |
| Almeida, AM | 1 |
| Bueso-Ramos, C | 1 |
| Ferrajoli, A | 1 |
| Cortes, J | 1 |
| Wierda, WG | 1 |
| Koller, C | 1 |
| Morris, G | 1 |
| Rosner, G | 1 |
| Loboda, A | 1 |
| Fantin, VR | 1 |
| Randolph, SS | 1 |
| Hardwick, JS | 1 |
| Reilly, JF | 1 |
| Chen, C | 1 |
| Ricker, JL | 1 |
| Secrist, JP | 1 |
| Richon, VM | 1 |
| Frankel, SR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II Study of Vorinostat in Combination With Low Dose Ara-C for Patients With Intermediate-2 or High Risk Myelodysplastic Syndromes[NCT00776503] | Phase 1/Phase 2 | 52 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| A Phase I Clinical Trial of Vorinostat in Combination With Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome[NCT00479232] | Phase 1 | 71 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Phase II Clinical Evaluation of Vorinostat Combined With Salvage Reinduction Chemotherapy Including Gemtuzumab Ozogamicin, Idarubicin and Cytarabine and Vorinostat Maintenance in Relapse or Refractory Acute Myeloid Leukemia Patients With 50 Years or Older[NCT01039363] | Phase 2 | 27 participants (Anticipated) | Interventional | Not yet recruiting | |||
| Phase II Randomised Trial of 5-azacitidine Versus 5-azacitidine in Combination With Vorinostat in Patients With Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndromes Ineligible for Intensive Chemotherapy[NCT01617226] | Phase 2 | 260 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants who received at least one dose of vorinostat in combination with decitabine intravenous (IV) at a dose of 20 mg/m^2 daily for 5 days along with oral vorinostat 400 mg once daily for 7 to 14 days in a 28-day cycle concurrently or sequentially, were evaluated to determine the maximum tolerable dose (MTD) determined by the number of participants experiencing dose limiting toxicity (DLT) events defined as any Grade 3 or 4 non-hematological toxicity (reported adverse event) and/or myelosuppression lasting >42 days. (NCT00479232)
Timeframe: Day 1 to 28 of Cycle 1
| Intervention | participants (Number) |
|---|---|
| Concurrent, Vorinostat 400mg qd x 7d/4wk + Decitabine | 0 |
| Concurrent, Vorinostat 400mg qd x 7d/2wk + Decitabine | 0 |
| Concurrent, Vorinostat 400mg qd x 14d/4wk + Decitabine (MTD) | 0 |
| Sequential, Vorinostat 400mg qd x 7d/4wk + Decitabine | 0 |
| Sequential, Vorinostat 400mg qd x 10d/4wk + Decitabine | 0 |
| Sequential, Vorinostat 400mg qd x 14d/4wk + Decitabine (MTD) | 1 |
Objective Response Rate was measured in participants with intermediate-high risk MDS or untreated AML who were treated with vorinostat and decitabine either on a concurrent or sequential regimen. The Objective response was defined as any confirmed complete remission or any confirmed partial remission for AML participants and complete remission, confirmed partial remission or confirmed hematologic improvement for MDS participants. (NCT00479232)
Timeframe: Approximately 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Untreated AML or Intermediate, Concurrent | 35.0 |
| Untreated AML or Intermediate, Sequential | 13.6 |
Objective Response Rate was measured in participants with refractory or relapse AML (acute myelogenous leukemia) in combination with Decitabine who were treated with vorinostat and decitabine on either a concurrent or sequential regimen. The Objective response was defined as any confirmed complete remission or any confirmed partial remission for AML participants and complete remission, confirmed partial remission or confirmed hematologic improvement for Myelodysplastic Syndrome (MDS) participants. (NCT00479232)
Timeframe: Approximately 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Refractory or Relapsed AML, Concurrent | 7.1 |
| Refractory or Relapsed AML, Sequential | 0.0 |
3 reviews available for vorinostat and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
More is better: combination therapies for myelodysplastic syndromes.
Topics: Antineoplastic Agents; Azacitidine; Benzamides; Clinical Trials as Topic; Decitabine; Disease Progre | 2015 |
Vorinostat in acute myeloid leukemia and myelodysplastic syndromes.
Topics: Antineoplastic Agents; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myeloid, | 2011 |
[Epigenetic therapy in myelodysplastic syndromes].
Topics: Azacitidine; Decitabine; Depsipeptides; DNA Methylation; DNA Modification Methylases; Drug Design; D | 2011 |
6 trials available for vorinostat and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2017 |
Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Do | 2014 |
A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitid | 2014 |
Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add-on study from the Groupe Francophone des Myelodysplasies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Disease-Free Survival; Humans; Ka | 2018 |
Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Fema | 2012 |
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials, Phase I as Topic; Dose-Res | 2008 |
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials, Phase I as Topic; Dose-Res | 2008 |
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials, Phase I as Topic; Dose-Res | 2008 |
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials, Phase I as Topic; Dose-Res | 2008 |
7 other studies available for vorinostat and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Improving Outcomes in High-Risk Myelodysplasia: Festina Lente.
Topics: Azacitidine; Humans; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Uni | 2017 |
Epigenetic Combination Therapy for Children With Secondary Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) and Concurrent Solid Tumor Relapse.
Topics: Adolescent; Antineoplastic Agents; Azacitidine; Decitabine; Drug Therapy, Combination; Epigenesis, G | 2017 |
The wolf of hypomethylating agent failure: what comes next?
Topics: Animals; Azacitidine; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Vorinostat; Wolves | 2019 |
Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodysplastic syndromes: produces stable disease but at the cost of high toxicity.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Histone Deacetylase Inhibitors; Humans; Hydroxamic | 2013 |
Clinical roundtable monograph. Combination therapies for MDS.
Topics: Azacitidine; Carrier Proteins; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic | 2009 |
Leukemia cutis in association With Grover's disease.
Topics: Acantholysis; Aged; Antineoplastic Agents; Biopsy; Dermis; Fatal Outcome; Flavonoids; Humans; Hydrox | 2011 |
Vorinostat induces apoptosis and differentiation in myeloid malignancies: genetic and molecular mechanisms.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Cell Cycle Checkpoints; Cell Differentiation; Cell | 2013 |